Secutrelvir for covid-19 patients at high risk
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new antiviral pill, secutrelvir, for people with mild to moderate covid-19 who are at higher risk of getting seriously ill. It aims to see if the drug can prevent hospitalization or severe disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 to 17 years old and weigh at least 88 pounds, or you are 18 or older (any weight).
- You have at least one symptom of covid-19 (like fever, cough, or loss of taste) that started within the last 3 days.
- You have a positive covid-19 test taken within the last 3 days.
- You have a health condition that puts you at higher risk of severe covid-19 (like diabetes, heart disease, or being older).
- You are not able or willing to take other available covid-19 antiviral medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody medicine for people with COVID-19 who are at high risk of getting very sick. If you qualify, you would receive the study drug or a placebo (inactive substance) to see if it helps you recover without needing to go to the hospital.
This trial studies a longer course of remdesivir combined with nirmatrelvir/ritonavir (Paxlovid) for immunocompromised patients who have persistent COVID-19. The goal is to see if this combination helps clear the virus better.
This trial tests updated COVID-19 vaccines designed to better protect against current variants. It's for people who have already been vaccinated and are at higher risk for severe COVID-19.
This study tests an experimental oral antiviral, secutrelvir, for people with mild to moderate COVID-19 who are not sick enough to need hospital care. The medicine aims to reduce symptoms and help you recover faster.
This trial tests if a new medicine called ibuzatrelvir can help people with COVID-19 who have certain health risks avoid severe illness. It is for patients who cannot or choose not to take another COVID-19 pill called Paxlovid.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
Hear when a new SARS CoV-2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.